Last reviewed · How we verify
CVM-1118
At a glance
| Generic name | CVM-1118 |
|---|---|
| Also known as | TRX-818 |
| Sponsor | TaiRx, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors (PHASE2)
- CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma (PHASE2)
- CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma (PHASE2)
- Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |